Clinical Trials Logo

Clinical Trial Summary

The goal of this study is to determine the impact of the food on the absorption of the ABX464.


Clinical Trial Description

This is a phase I, single-center, open-label, two-treatment, food-effect, randomized study in 40 healthy Caucasian male subjects in order to determine the impact of the food on the absorption of the ABX464.

The two different treatments are the followings:

- Treatment A = 50mg of ABX464 (two 25mg capsules) /Fasted

- Treatment B = 50mg of ABX464 (two 25mg capsules) / Fed

This study consists of two groups:

- Group 1 - single dose assessments, two-period, two-treatment, cross-over: 20 subjects will receive a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.

- Group 2 - multiple dose assessments: 20 subjects will receive 50mg of ABX464 every 3 days during 10 days in fasted or fed condition. ;


Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02731885
Study type Interventional
Source Abivax S.A.
Contact
Status Completed
Phase Phase 1
Start date September 2014
Completion date June 2015

See also
  Status Clinical Trial Phase
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Recruiting NCT02543983 - Neurobiology of Suicide Phase 2
Completed NCT00995527 - Characterization of the Innate Immune Response in Healthy NIH Employees at Baseline and After Immunization With the H1N1 Vaccine N/A
Recruiting NCT03662191 - Phase I Safety, Pharmacokinetics and Bioavailability Study Comparing Rate and Extent of Absorption of Two Different Forms of Tafamidis (PF-6291826) Phase 1
Recruiting NCT03314402 - The Tolerance, Pharmacokinetics of Jaktinib in Healthy Volunteers Phase 1
Completed NCT01136928 - Pharmacokinetic Interaction Study of Efavirenz and American Ginseng in Healthy Volunteers Phase 1
Enrolling by invitation NCT02796001 - Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in Humans Phase 1/Phase 2
Completed NCT03194139 - A Study Designed to Compare the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 and GC4419 in Healthy Volunteers Phase 1
Completed NCT03201835 - 5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers Phase 1
Recruiting NCT01851421 - Fat Metabolism and Melanocortin 3 Receptors in African Americans
Completed NCT03276858 - Single and Multiple-Ascending Dose Study of CRN00808 in Healthy Volunteers Phase 1
Recruiting NCT03648892 - Brain Dopamine Function in Human Obesity
Recruiting NCT03169673 - Healthy Lung Study- Development of 3 Tesla MRI Hardware and Software for Helium-3 Gas Imaging of the Lung: Healthy Volunteer Development Study
Recruiting NCT03390673 - A Trial to Demonstrate the Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects Phase 1
Recruiting NCT02825368 - Homeopathic Vaccine Trial Phase 4
Recruiting NCT02910973 - Using a Transcutaneous Electrical Auricular Stimulator to Harness the Cholinergic Anti-Inflammatory Pathway N/A
Active, not recruiting NCT02932488 - Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation Phase 1